VCEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VCEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Vericel has the Growth Rank of 9.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Biotechnology subindustry, Vericel's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vericel's Growth Rank distribution charts can be found below:
* The bar in red indicates where Vericel's Growth Rank falls into.
Thank you for viewing the detailed overview of Vericel's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Dominick Colangelo | director, officer: President and CEO | 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451 |
Zerbe Robert L Md | director | |
Paul K Wotton | director | C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341 |
Sean C. Flynn | officer: SVP, General Counsel | C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139 |
Michael Halpin | officer: Chief Operating Officer | C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139 |
Jonathan Mark Hopper | officer: Chief Medical Officer | 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
Jonathan Siegal | officer: Principal Accounting Officer | C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
Lisa Wright | director | C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
Mara Joseph Anthony Jr | officer: Chief Financial Officer | C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Sandra Pennell | officer: VP and Corporate Controller | C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
Gerard J Michel | officer: CFO & VP , Corp. Development | 420 CHIPETA WAY, SALT LAKE CITY UT 84108 |
Daniel Orlando | officer: Chief Operating Officer | P.O. BOX 376, ANN ARBOR MI 48105 |
Alan L Rubino | director | PO BOX 376, LOBBY L., ANN ARBOR MI 48105 |
Consonance Capital Management Lp | 10 percent owner | 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019 |
From GuruFocus
By GuruFocus Research • 11-08-2023
By GuruFocusNews GuruFocusNews • 02-10-2022
By Marketwired • 11-07-2023
By Marketwired • 09-06-2023
By GuruFocusNews GuruFocusNews • 03-01-2022
By PurpleRose PurpleRose • 07-20-2022
By GuruFocusNews GuruFocusNews • 02-02-2022
By sperokesalga sperokesalga • 02-09-2023
By Marketwired • 07-20-2023
By sperokesalga sperokesalga • 02-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.